Evidence map›Paper›PMID 39833501›Full record

ArticleAnalytical and bioanalytical chemistry2025

Full sequencing of 100mer sgRNA via tandem mass spectrometry by targeted RNase H digestion with customized probes.

Christopher Gawlig, Rebecca Hirschberger, Güngör Hanci, Saskia Schott, Shima Marandi, Ida Ronja Hesse, Michael Rühl

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christopher GawligBiospring Gesellschaft für Biotechnologie, Alt-Fechenheim 34, Frankfurt am Main, 60386, Germany.
Rebecca HirschbergerBiospring Gesellschaft für Biotechnologie, Alt-Fechenheim 34, Frankfurt am Main, 60386, Germany.
Güngör HanciBiospring Gesellschaft für Biotechnologie, Alt-Fechenheim 34, Frankfurt am Main, 60386, Germany.
Saskia SchottBiospring Gesellschaft für Biotechnologie, Alt-Fechenheim 34, Frankfurt am Main, 60386, Germany.
Shima MarandiBiospring Gesellschaft für Biotechnologie, Alt-Fechenheim 34, Frankfurt am Main, 60386, Germany.
Ida Ronja HesseBiospring Gesellschaft für Biotechnologie, Alt-Fechenheim 34, Frankfurt am Main, 60386, Germany.
Michael RühlBiospring Gesellschaft für Biotechnologie, Alt-Fechenheim 34, Frankfurt am Main, 60386, Germany. ruehl@biospring.de.ORCID http://orcid.org/0000-0002-2312-8141

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of single-guide RNA (sgRNA) for gene editing using the CRISPR Cas9 system has become a powerful technique in various fields, especially with the growing interest in such molecules as therapeutic options in the last years. An important parameter for the use of these molecules is the verification of the correct sgRNA oligonucleotide sequence. Apart from next-generation sequencing protocols, mass spectrometry (MS) has been proven as a powerful technique for this purpose. The protocol and investigations presented in this work show an optimal digestion and 100% sequence coverage of sgRNA, while top-down approaches or other ribonuclease (RNase) digestion strategies obtain a sequence coverage of up to 80-90% utilizing multiple RNases. The results in this publication were obtained by utilizing DNA-RNA hybrid GAPmer-like probes and RNase H, an enzyme which specifically hydrolyzes RNA in DNA-RNA double strands. We assessed the optimal length of the DNA segment of these hybrid probes to maximize the specificity of the RNase H digestion and to achieve complete sequence confirmation by tandem MS analysis of the resulting digestion products. Furthermore, we showed that the approach is applicable for the identification of common synthesis-related impurities, like truncations and elongations. Despite the fact that the accessibility of this approach for highly modified molecules is limited to nucleotides which are not 2'-O-methylated, the optimized sequence coverage makes it a viable method.

Indexed as

Ribonuclease HRNA, Guide, CRISPR-Cas SystemsTandem Mass SpectrometryGene EditingHigh-Throughput Nucleotide SequencingRibonuclease HRNA, Guide, CRISPR-Cas SystemsCRISPR-CasMass spectrometryRNAse HSingle-guide RNA

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.